BridgeBio Oncology Therapeutics, Inc. Insider Trading
BBOT
Insiders sold 4K and bought nothing on the open market.
All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Feb 2024.
Get an email when BBOT's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| Nov 18 | Pedro Beltran President and CEO | Sold10b5-1 plan | 1,870 | $1.84 | 3K | 4.3% | Form 4 |
| Nov 13 | Marc Cobo Principal Accounting Officer | Sold10b5-1 plan | 78 | $2.37 | $185 | 0.6% | Form 4 |
- Nov 1810b5-1 planPedro BeltranPresident and CEO · sold 1,870 at $1.843K4.3% of stake
- Nov 1310b5-1 planMarc CoboPrincipal Accounting Officer · sold 78 at $2.37$1850.6% of stake
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Pharmaceutical Preparations · Pick stocks to compare with BBOT
Held by ETFs
BBOT is in 7 US ETFs. The largest of them, with BBOT's weight in each:
State Street SPDR S&P Biotech ETFXBI0.02%of the fund
iShares Biotechnology ETFIBB0.01%of the fund
Direxion Daily S&P Biotech Bull 3X SharesLABU0.05%of the fund
- CATema Oncology ETFCANC0.48%of the fund
- BBVirtus Biotech Clinical Trials ETFBBC0.70%of the fund
Harbor Active Small Cap Growth ETFSGRW0.37%of the fund
Spot a number that looks wrong? Check it in BBOT's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing BBOT
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.